Hepatitis Test Market by Technology (ELISA, RDT, PCR, Transcription Mediated Amplification) and Disease Type (Hepatitis B, HCV, HAV, HDV) to 2023

Key players in hepatitis test solution/diagnosis market are Roche (Switzerland), Abbott Laboratories (US), Bio-Rad (US), Siemens (Germany), DiaSorin (Italy), QIAGEN (Netherlands), Danaher (US), bioMérieux (France), and Grifols (Spain).

Hepatitis test solution/diagnosis market is expected to reach USD 3.37 billion by 2023 from USD 2.66 billion in 2018, growing at a CAGR of 4.9% during forecast period. Growth of this market can be attributed to high burden of hepatitis worldwide, benefits offered by point of care instruments & kits, and initiatives taken by government and non-government organizations.

Get Free Sample Papers Now at http://www.rnrmarketresearch.com/contacts/request-sample?rname=1724316 .

Major players in hepatitis diagnosis market were identified through secondary research, and their market revenues were determined through primary and secondary research. Secondary sources include annual reports, press releases, and investor presentations of companies; white papers; medical journals; certified publications; articles from recognized authors; gold standard and silver standard websites; directories; and databases.

Hepatitis diagnosis market is primarily driven by factors such as the high burden of hepatitis worldwide, increasing number of blood transfusions and donations, benefits offered by PoC instruments & kits, and awareness initiatives. Emerging markets such as China, India, Brazil, and Africa are expected to offer lucrative growth opportunities for the players in this market. However, the high cost of NAT tests and a lack of mandate for NAT in developing countries are expected to restrain the growth of this market during the forecast period.

Get Details Now at www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=1724316 .

The hepatitis diagnosis market is classified on the basis of disease type into hepatitis B, hepatitis C, and other hepatitis disease. In terms of value, the hepatitis B segment is expected to account for the largest share of the market in 2018.This can primarily be attributed to therising prevalence of hepatitis B, availability of a large number of hepatitis B diagnostic tests, and the increasing adoption of NAT test in HBV blood screening.

North America is expected to account for the largest share of the global hepatitis diagnosis market in 2018. This is primarily attributed to factors such as rising adoption of advanced technologies, developed healthcare systems in US and Canada, and the presence of a large number of leading national clinical laboratories. Followed by North America, Europe is expected to account for the second-largest share of the global hepatitis test solution/diagnosis market in 2018.

Target Audience:
• Blood banks
• Pathologists and pathology laboratories
• Distributors of IVD products
• Research institutes
• Hospitals and clinics
• Healthcare institutions
• Group purchasing organizations (GPOs)
• Market research and consulting firms

Order the “Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis B, HCV, HAV, HDV), Technology (ELISA, RDT, PCR, Transcription Mediated Amplification), End User (Hospitals, Diagnostic Laboratories, Blood Banks, Nursing Homes) - Global Forecast to 2023” report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=1724316 .

Geographically, the hepatitis test solution/diagnosis market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018 North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market.

Break-up profile of primaries:
• By Company Type- Tier 1-32%, Tier 2-42% and Tier 3-26%
• By Designation-C-level-23%, D-level-35% and Others-42%
• By Region-North America-39%, Europe-25%, Asia Pacific-26%,and RoW-10%

The APAC region is projected to grow at the highest CAGR during the forecast period. The growth of the hepatitis test solution/diagnosis market in this region is driven by the widespread prevalence of hepatitis infections, increased healthcare spending by a larger population base, and modernization of healthcare infrastructure.

Contact Info:
Name: Mr. Vishal
Email: Send Email
Organization: RnRMarketResearch
Address: Tower B5, Office 101, Magarpatta City SEZ, Pune-411013, India
Phone: +1 888 391 5441
Website: http://www.rnrmarketresearch.com/hepatitis-test-solution-diagnosis-market-by-disease-type-hepatitis-b-hcv-hav-hdv-technology-elisa-rdt-pcr-transcription-mediated-amplification-end-user-hospitals-diagnostic-laboratories-blood-banks-n-st-to-2023-market-report.html

Release ID: 433433